DCOY · Decoy Therapeutics Inc. · Executive Compensation
$1.67
-0.10 (-5.65%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.29M
Shares
655,185
Volume · Oct 5
108.01K
Avg daily vol (3M)
2.13M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark J. Rosenblum | Executive Vice President, Finance and Chief Financial Officer | $350,422 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark J. Rosenblum | Executive Vice President, Finance and Chief Financial Officer | $355,760 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David J. Arthur | President and Chief Executive Officer Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | $941,023 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David J. Arthur | President and Chief Executive Officer Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer | $676,755 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| William K. McVicar | Former Chief Executive Officer of Flex Pharma, Inc. | $1,160,523 |
| Scott Jordan | Former Chief Business Officer | $296,008 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| William K. McVicar | Former Chief Executive Officer of Flex Pharma, Inc. | $1,798,404 |
| Scott Jordan | Former Chief Business Officer | $158,047 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter Marschel | Chief Business Officer | Appointed | 2025-11-19 |
| Barbara Hibner | Chief Scientific Officer | Appointed | 2025-11-19 |
| Frederick E. Pierce | Chief Executive Officer | Appointed | 2025-11-19 |
| Barbara Hibner | Chief Scientific Officer | Appointed | 2025-11-13 |
| Peter Marschel | Chief Business Officer | Appointed | 2025-11-13 |
| Frederick E. Pierce | Chief Executive Officer | Appointed | 2025-11-13 |
| Bruce J. McCreedy | Board of Directors | Resigned | 2025-11-13 |
| Frederick E. Pierce | Class II director | Appointed | 2025-11-13 |
| David J. Arthur | Chief Executive Officer | Resigned | 2025-08-18 |
| Mark J. Rosenblum | acting Chief Executive Officer | Appointed | 2025-08-18 |